Beaumont Financial Partners, LLC Gilead Sciences, Inc. Transaction History

Beaumont Financial Partners, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$57.72 - $65.01 $362,366 - $408,132	-6,278 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$57.92 - $72.58 $1,563 - $1,959	27 Added 0.43%	6,278 $373,000
Q4 2021 Feb 07, 2022	BUY	$64.88 - $73.64 $7,590 - $8,615	117 Added 1.91%	6,251 $454,000
Q3 2021 Nov 12, 2021	SELL	$67.69 - $73.03 $6,836 - $7,376	-101 Reduced 1.62%	6,134 $428,000
Q1 2021 May 04, 2021	SELL	$60.0 - $68.46 $5,760 - $6,572	-96 Reduced 1.52%	6,235 $403,000
Q4 2020 Feb 08, 2021	SELL	$56.65 - $64.55 $21,980 - $25,045	-388 Reduced 5.77%	6,331 $369,000
Q3 2020 Nov 02, 2020	BUY	$62.1 - $78.08 $23,660 - $29,748	381 Added 6.01%	6,719 $425,000
Q2 2020 Aug 05, 2020	BUY	$72.34 - $84.0 $9,548 - $11,088	132 Added 2.13%	6,338 $488,000
Q1 2020 May 08, 2020	BUY	$62.63 - $80.22 $388,681 - $497,845	6,206 New	6,206 $464,000
Q4 2018 Feb 07, 2019	SELL	$60.54 - $79.0 $250,272 - $326,586	-4,134 Closed	0 $0
Q3 2018 Nov 02, 2018	BUY	$71.28 - $78.92 $294,671 - $326,255	4,134 New	4,134 $319,000

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Beaumont Financial Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Beaumont Financial Partners, LLC with notifications on news.